Milnacipran is a medicine used to help treat fibromyalgia. Fibromyalgia is a condition that causes widespread muscle pain, fatigue, and tenderness. Milnacipran works by affecting chemicals in your brain that help control pain and mood. It's often taken once a day.
Every report comes from a Lived member, sent anonymously.
Have you tried Milnacipran for Fibromyalgia?
Milnacipran, sold under the brand name Savella and as a generic, is a prescription tablet approved in the US for managing fibromyalgia in adults. Fibromyalgia is a long-term condition marked by widespread pain, fatigue and poor sleep. Milnacipran is used to ease the pain, and in clinical trials some people also reported better overall wellbeing and physical function. It belongs to a group of medicines called serotonin and norepinephrine reuptake inhibitors (SNRIs), the same broad family as some antidepressants. Even so, in the US it is not approved to treat depression, and it is not approved for anyone under 18. Other medicines approved for fibromyalgia include duloxetine (Cymbalta), another SNRI, pregabalin (Lyrica), a medicine also used for nerve pain, and Tonmya, a form of cyclobenzaprine that dissolves under the tongue. In studies comparing milnacipran, duloxetine and pregabalin indirectly, none clearly outperformed the others, so the choice often comes down to side effects, other health conditions and other medicines a person takes. Medication is usually not the first step. Fibromyalgia guidelines recommend starting with education and non-drug approaches, especially regular exercise, and adding a medicine like milnacipran when pain remains severe.
Serotonin and norepinephrine are chemical messengers that nerve cells use to communicate. Among their jobs, they help the brain and spinal cord turn down the volume on pain signals. After a nerve cell releases them, it normally reabsorbs them, which ends their effect. Milnacipran slows that reabsorption, leaving more of both messengers active. It acts more strongly on norepinephrine than on serotonin. This is thought to strengthen the body's own pain-dampening pathways in the brain and spinal cord rather than acting at the place that hurts. The exact way it eases fibromyalgia symptoms is not known. The extra norepinephrine activity also explains some of its side effects, such as a faster heartbeat, higher blood pressure and sweating.
Milnacipran is taken by mouth twice a day, with or without food. Taking it with food may make nausea less likely. Treatment starts at a low dose that is stepped up over the first week, often using a starter pack, to reach the usual dose of 100 mg a day (50 mg twice daily). Depending on response, the prescriber may raise it to 200 mg a day, the highest dose studied. In the main trials, the higher dose did not provide more relief on average and caused more people to stop because of side effects. People with severe kidney disease usually need a lower dose, because the kidneys clear most of the medicine, and it is not recommended for people with end-stage kidney disease. If a dose is missed, take it when remembered unless the next dose is nearly due, in which case skip it; do not take two doses at once. After regular use, do not stop milnacipran suddenly. Reducing the dose gradually with the prescriber's guidance helps avoid withdrawal symptoms such as dizziness, irritability, headache and brief electric shock sensations.
Nausea is the most common side effect: more than a third of people in clinical trials had it, compared with about a fifth on placebo. It is most noticeable early on. Other common effects include constipation, headache, dizziness, trouble sleeping, hot flashes, heavy sweating, a pounding or fast heartbeat, dry mouth and vomiting. In trials, roughly a quarter of people stopped milnacipran because of side effects, about twice the rate on placebo. Sexual side effects, such as lower desire or delayed orgasm, can occur in anyone and are worth raising rather than quietly tolerating. Men may also have difficulty or pain when urinating, testicular pain or ejaculation problems, especially with an enlarged prostate. A few reactions need attention. Yellowing of the skin or eyes can signal liver injury and should be reported to the prescriber right away. Headache, confusion, weakness or unsteadiness, particularly in older adults or people taking diuretics (water pills), can reflect low blood sodium and also warrant a prompt call. Serotonin syndrome, a rare reaction caused by too much serotonin activity, can bring mental changes such as agitation, confusion or hallucinations; a fast heartbeat, fever and heavy sweating; shaking, muscle stiffness or twitching; and nausea or diarrhea. Get medical care right away if these symptoms appear.
Like antidepressants, milnacipran carries a boxed warning from the US Food and Drug Administration (FDA): these medicines increased suicidal thoughts and behaviors in some children, teenagers and young adults in short-term studies. Anyone starting milnacipran, at any age, should be watched for worsening mood, new anxiety, agitation, panic, irritability, impulsive behavior or suicidal thoughts, especially in the first weeks and after a dose change. Family members can help notice these changes, and they should be reported to the prescriber promptly. Milnacipran must not be combined with MAOIs (monoamine oxidase inhibitors), an older class of antidepressants. At least 14 days must pass after stopping an MAOI before starting milnacipran, and at least 5 days after stopping milnacipran before starting an MAOI. It also should not be started in someone receiving linezolid, an antibiotic, or intravenous methylene blue, both of which act like MAOIs. Other medicines that raise serotonin add to the risk of serotonin syndrome, including other antidepressants, triptans for migraine, tramadol and some other opioid pain medicines, lithium (a mood stabilizer), amphetamines (stimulants such as those used for ADHD) and the supplement St. John's wort. Because milnacipran affects how platelets help blood clot, combining it with aspirin, ibuprofen, naproxen or blood thinners such as warfarin raises the risk of bleeding. Blood pressure and heart rate are checked before starting and periodically during treatment, since milnacipran can raise both. High blood pressure or heart rhythm problems are usually treated first. It is ordinarily not prescribed to people who drink substantial amounts of alcohol or have chronic liver disease. Caution is also needed with a history of seizures, mania, urinary blockage or narrow-angle glaucoma, a type of glaucoma in which eye pressure can rise suddenly. Sudden eye pain, vision changes such as seeing halos, or redness or swelling around the eye need prompt medical care. The data on milnacipran in pregnancy are too limited to judge its effect on birth defects. Use in the month before delivery may increase the risk of heavy bleeding after birth, and babies exposed late in pregnancy have sometimes needed extra care after delivery. Milnacipran passes into breast milk. Anyone pregnant, planning pregnancy or breastfeeding should discuss it with the prescriber.
Milnacipran helps some people meaningfully, but not most. In a review of six trials with more than 4,000 adults, about 40% of people taking it had their pain reduced by at least 30%, compared with about 30% on placebo. Among those who did respond, some noticed less pain within the first week of reaching a steady dose. Side effects, especially nausea, often appear before any benefit and tend to be worst during the first weeks of dose increases. Follow-up visits are used to check blood pressure and heart rate, review side effects and judge whether pain, sleep and daily function have improved enough to justify continuing. If milnacipran is not helping or is hard to tolerate, the prescriber may adjust the dose or try a different approach. It works best as one part of a broader plan that includes exercise and other fibromyalgia self-care. If it is stopped, the dose is reduced gradually.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Milnacipran, what you've noticed, or ask the community a question.